Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

China Resources and Roche Partner on Trastuzumab Emtansine Commercialization to Expand Breast Cancer ADC Access

Fineline Cube Apr 14, 2026
Company Deals

CTTQ and Teva Partner on Treanda Commercialization to Expand Bendamustine Access in China’s NHL Market

Fineline Cube Apr 14, 2026
Company Deals

Erasca Exercises Option to Secure Global Rights to Pan-RAS Molecular Glue ERAS-0015 from Joyo Pharmatech

Fineline Cube Apr 14, 2026
Company Deals

Zuellig Pharma Acquires Cialis Rights for Hong Kong, Macau, and South Korea from Eli Lilly

Fineline Cube Apr 14, 2026
Company Deals

Olymvax Biopharmaceuticals and Westlake University Launch Universal Influenza Vaccine Collaboration

Fineline Cube Apr 14, 2026
Policy / Regulatory

China’s NHSA Selects 31 Innovative Drugs for Historic Reference Drug Pre-Communication Program

Fineline Cube Apr 14, 2026
Company Drug

Grand Pharmaceutical’s SIR-Spheres Achieves Phase III Success in Unresectable HCC, Supporting China Expansion

Fineline Cube Apr 14, 2026
Company Drug

Zelgen’s Jaktinib Hits Primary Endpoint in Phase III Atopic Dermatitis Trial – Dual JAK/ACVR1 Inhibitor Expands Beyond Myelofusion

Fineline Cube Apr 14, 2026
Company Drug

Zelgen Biopharmaceuticals’ Jacktinib Wins FDA Approval for Severe Alopecia Areata

Fineline Cube Sep 5, 2022

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) secured U.S. FDA approval to launch a clinical...

Company Drug

Jacobio Pharmaceuticals Doses First Patient in JAB-BX102 Phase I/IIa Trial for CD73-Targeted Cancer Therapy

Fineline Cube Sep 5, 2022

China’s Jacobio Pharmaceuticals Group Co., Ltd (HKG: 1167) announced the first patient dosed in a...

Company Deals Drug

Northeast Pharma Licenses MedAbome’s MAb11-22.1 for ADC and CAR-T Development

Fineline Cube Sep 5, 2022

China’s Northeast Pharmaceutical Co., Ltd (SHE: 000597) has signed a licensing agreement with U.S.-based MedAbome...

Company Drug

Alphamab Oncology Highlights KN046, KN026 Advances at ESMO 2022

Fineline Cube Sep 5, 2022

China’s Alphamab Oncology (HKG: 9966) will present updated clinical data for its bispecific antibody candidates...

Company Drug

AstraZeneca’s Farxiga Wins China Approval for Chronic Kidney Disease

Fineline Cube Sep 5, 2022

UK pharma giant AstraZeneca (AZ, NASDAQ: AZN) announced a new approval for Farxiga (dapagliflozin), its...

Company Drug

Innovent Biologics Doses First Patient in Higher-Dose Mazdutide Obesity Trial

Fineline Cube Sep 5, 2022

China’s Innovent Biologics, Inc. (HKG: 1801) announced that the first participant has been dosed in...

Company Drug

Shanghai Pharma’s CD20 Antibody Advances to Primary Nephropathy Trial After NMPA Approval

Fineline Cube Sep 5, 2022

China’s Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607) has received approval from the National Medical Products...

Company Drug

Walvax Biotech Wins NMPA Approval for mRNA and Recombinant COVID-19 Vaccines

Fineline Cube Sep 2, 2022

China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has received clinical trial approvals from the National...

Company Deals

Medim Science Raises Funds for Macrophage-Targeting Biologics in Cancer Therapy

Fineline Cube Sep 2, 2022

Hangzhou-based Medim Science, China’s first pharma firm focused on macrophage-targeting biologics, has reportedly raised tens...

Drug Medical Device

China’s Pharmaceutical Industry Sees Revenue Decline Amid Export Shifts

Fineline Cube Sep 2, 2022

China’s pharmaceutical manufacturing sector reported a 1.8% year-on-year (YOY) revenue decline to RMB 1.6 trillion...

Company Deals

Tibet Duo Rui and Nanjing Heron Forge Pharmaceutical Collaboration in China

Fineline Cube Sep 2, 2022

China-based Tibet Duo Rui Pharmaceutical Co., Ltd and Nanjing Heron Pharmaceutical Science and Technology Co.,...

Company Drug

CARsgen Therapeutics Launches GMP Manufacturing for CAR-T Cell Therapies in North Carolina

Fineline Cube Sep 2, 2022

China’s CARsgen Therapeutics Holdings Ltd (HKG: 2171), a chimeric antigen receptor (CAR)-T cell specialist, has...

Company Deals

MegaRobo and Danaher Life Sciences Partner on Lab Automation in China

Fineline Cube Sep 2, 2022

Beijing-based MegaRobo Technologies, a robotics and AI firm in life sciences, has partnered with Danaher...

Company Drug

Hengrui Medicine’s HRG2101 Inhaler Wins NMPA Approval for IPF Clinical Trial

Fineline Cube Sep 2, 2022

China’s Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has received approval from the National Medical...

Company Deals

U Protech Secures Angel Financing for PROTAC and Molecular Glue Drug Pipeline

Fineline Cube Sep 2, 2022

U Protech, a Hangzhou-based biotech focused on next-generation protein degradation therapies, has raised tens of...

Company Deals Digital

J&J China, Tencent Launch Digital Rhinitis Platform “Love Nose e-Station”

Fineline Cube Sep 2, 2022

Johnson & Johnson’s (J&J, NYSE: JNJ) J&J China Self Care and China’s Tencent have launched...

Company Deals

Neukio Biotherapeutics Completes USD 50M Series A-1 Financing for iPSC-CAR-NK Therapy

Fineline Cube Sep 2, 2022

Shanghai-based Neukio Biotherapeutics, a developer of iPSC-derived chimeric antigen receptor natural killer (CAR-NK) cell therapies,...

Company Deals

Acorda Therapeutics Licenses Preclinical Drug Nepicastat to China’s Asieris

Fineline Cube Sep 2, 2022

US-based Acorda Therapeutics Inc. (Nasdaq: ACOR) announced a licensing agreement with China’s Asieris Pharmaceuticals for...

Policy / Regulatory

SAMR Issues New Rules for Online Drug Sales in China

Fineline Cube Sep 2, 2022

China’s State Administration for Market Regulation (SAMR) has released the “Measures for the Supervision and...

Policy / Regulatory

NMPA Designates Shijiazhuang Airport as Drug Import Port for Narcotics, Psychotropics

Fineline Cube Sep 2, 2022

China’s National Medical Products Administration (NMPA) has designated Shijiazhuang Airport in Hebei Province as an...

Posts pagination

1 … 613 614 615 … 650

Recent updates

  • Grand Pharmaceutical’s SIR-Spheres Achieves Phase III Success in Unresectable HCC, Supporting China Expansion
  • China Resources and Roche Partner on Trastuzumab Emtansine Commercialization to Expand Breast Cancer ADC Access
  • Zelgen’s Jaktinib Hits Primary Endpoint in Phase III Atopic Dermatitis Trial – Dual JAK/ACVR1 Inhibitor Expands Beyond Myelofusion
  • China’s NHSA Selects 31 Innovative Drugs for Historic Reference Drug Pre-Communication Program
  • CTTQ and Teva Partner on Treanda Commercialization to Expand Bendamustine Access in China’s NHL Market
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Grand Pharmaceutical’s SIR-Spheres Achieves Phase III Success in Unresectable HCC, Supporting China Expansion

Company Deals

China Resources and Roche Partner on Trastuzumab Emtansine Commercialization to Expand Breast Cancer ADC Access

Company Drug

Zelgen’s Jaktinib Hits Primary Endpoint in Phase III Atopic Dermatitis Trial – Dual JAK/ACVR1 Inhibitor Expands Beyond Myelofusion

Policy / Regulatory

China’s NHSA Selects 31 Innovative Drugs for Historic Reference Drug Pre-Communication Program

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.